QALYs in Cost-Effectiveness and Benefit-Cost Analysis: How to be an Informed Consumer, Society for Benefit-Cost Analysis, Washington, District of Columbia, USA, March 18, 2015 (workshop).

2014 Discrete Choice Experiments: Enhancing PRO beyond QALY, Centre for Health Economics

Teaching and Training Experience

Graduate Training:

2024-present	Jelke te Focht, Health Technology and Services Research, Department of Technology, Policy and Society, University of Twente, Enschede, the Netherlands. Served as external advisor on Masters thesis and currently mentoring.
2020-2024	Maksat Jumamyradov, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair on dissertation committee and mentored for 5 years.
2018-2022	Suzana Karim, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair on dissertation committee and mentored for 5 years.
2021	Md Shahjahan, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 semester.
2016-2020	Stephen Poteet, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair on dissertation committee and mentored for 5 years.
2014-2018	John Hartman, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair of Dissertation Committee and mentored for 5 years.
2015-2016	Edson Santoro, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 year.
2009-2016	Shannon Runge, Aging Studies Program, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 7 years.
2014-2015	Kathleen McFadden, College of Medicine, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 year.
2010-2013	

Title:	Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes [R01-DA037961-01A1]
% Effort	3%
Role in the Study:	**Co-Investigator** Contributions include the proposal, design, conduct and publication of a cost-effectiveness study.
Total Direct Costs:	$ 2,404,256
Total Amount of Award:	$ 3,596,594
Grant Account:	
PI:	**Meade, CD** and **Gwede, CK**
Dates:	09/03/2010-08/31/2015
Source:	NCI
Title:	

Role:	**Co-Investigator** Contributions include the proposal, administration, design, conduct and publication of a value of information study and 3 secondary data analysis of Medicare claims.
Total Direct Costs:	$ 1,231,132
Total Amount of Award:	$ 3,963,447

PI:	**Craig, BM**
Dates:	09/01/2006-08/31/2011
Source:	NCI
Title:	Obesity, Aging and Cancer Cost (OACC) Study [K25-CA122176]
% Effort:	75%
Role in the Study:	**Principal Investigator**
Total Direct Costs:	$ 667,227
Total Amount of Award:	$ 720,604

PI/Co-PI:	**Jacobsen, P**
Dates:	03/30/2009-08/31/2009
Source:	NCI
Title:	Moffitt Aging and Cancer Prevention Program [P20-CA103676]
% Effort:	8%
Role in the Study:	**Co-Investigator**
Total Direct Costs:	$ 623,519
Total Amount of Award:	$ 1,041,277

PI:	**Lengacher, C**
Dates:	09/22/2009-09/21/2010
Source:	NCI
Title:	MBSR Symptom Cluster Trial for Breast Cancer Survivors [R01-CA131080-01A2]
% Effort:	5%
Role in the Study:	**Co-Investigator** Contributions include the proposal and advising on the design, conduct and publication of a cost-effectiveness study.
Total Direct Costs:	$ 593,504
Total Amount of Award:	Unknown

PI/Co-PI:	**Babcock-Parziale, J**
Dates:	04/01/2006-09/01/2006 [Withdrawn due to K-Award]
Source:	Veterans Affairs
Title:	Advancing Outcomes Measurement and Micro-costing in Blind Rehabilitation
% Effort:	20%
Role in the Study:	**Co-Investigator** Contributed to proposal and design of cost-effectiveness study.
Total Direct Costs:	Unavailable
Total Amount of Award:	$ 508,053

Grant Account:	R03-HS013993
PI/Co-PI:	**Craig, BM**

Dates: 07/1/2013-12/31/2013
Source: EuroQol Research Foundation
Title: The Relationship between Time, Sequencing and Precision
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: $ 32,253

PI: **Craig, BM**
Dates: 07/1/2013-12/31/2013
Source: EuroQol Research Foundation
Title: Preference Inversion in the EQ-5D-5L
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: $ 11,957
Total Amount of Award: $ 11,957

PI: **Craig, BM**
Dates: 03/01/2009-2/28/2011
Source: International Papillomavirus Society
Title: Pre-Conference on Modeling Evidence in HPV
% Effort: 1%
Role in the Study: **Principal Investigator**
Total Direct Costs: $ 200,000
Total Amount of Award: $ 200,000

PI/Co-PI: **Goode, K**
Dates: 01/01/2007-12/31/2007
Source: 2 - P3-1.4 (re)]TJ1.333 0 Td 500(9)(-)Tj0.003 TcEv
Danc[(Da)3. B-0.001u3 (l)2.45 (udy:4.3 (euP)1.f0. Py7F)1 Td[(Da)3.e (a)4.3 (l)2.

Title:	Pilot Study of SEER-Medicare Database to Define MDS Incidence
% Effort:	5%
Role in the Study:	**Co-Principal Investigator**
Total Direct Costs:	$ 60,673
Total Amount of Award:	$ 75,841

PI:	**Craig, BM**
Dates:	08/01/2008-12/31/2008
Source:	Merck
Title:	Evidence Synthesis for Modeling the Natural History of HPV-related Anal, Penile and Oropharyngeal Cancers
% Effort:	25%
Role in the Study:	**Principal Investigator**
Total Direct Costs:	$ 60,198
Total Amount of Award:	$ 99,928

PI:	**Skrepn3 (e)2.1sp30 Tc 34 0 Td001 Tw 4f0 Td( ]TJ/TT0.8 0.001 Tw 0 -1.153 TD**

Dates:	08/01/2005
Source:	CVS Pharmacy
Title:	Sponsorship of Educational Materials
Role in the Study:	**Coordinator**
Total Amount of Award:	$ 279

PI:	**Craig, BM**
Dates:	11/01/2004
Source:	Caremark PCS
Title:	Sponsorship of Educational Materials
Role in the Study:	**Coordinator**
Total Amount of Award:	$ 6,222

Consultant:

Grant Account:	NIHR127844
PI:	Knight, M
Dates:	01/10/2020-30/09/2025
Source:	UK NIHR
Title:	Improving unwarranted variation in outcomes of children's surgery through a new Children's Surgery Outcome Reporting system using routinely available data (CSOR)
% Effort:	0%
Role in the Study:	**Consultant** Contributions include the proposal, design, conduct and publication of a stated-preference study.
Total Direct Costs:	Not Applicable
Total Amount of Award:	£ 2,177,431

Grant Account:	200-2008-27958, TO 26
PI:	**Trogdon, JG**
Dates:	09/01/2011 - 08/31/2013
Source:	CDC
Title:	Economic Burden of Breast Cancer in Young Women Aged 15-44 Years in the United States, 2000-2010
% Effort:	0%
Role in the Study:	**Consultant** Contributions include the proposal, design, conduct and publication of an outcomes study.
Total Direct Costs:	$245,199
Total Amount of Award:	Unknown

Grant Account:	200-2008-F-26463
PI:	**Brown, DS**
Dates:	07/22/2008 – 07/31/2012
Source:	CDC
Title:	Preference-Based Assessment of Child Maltreatment and Quality of Life
% Effort:	0%
Role in the Study:	**Consultant** Contributions include the design, conduct and publication of a discrete choice experiment.

3. Jumamyradov M, **Craig BM**, Jakubczyk M. Scale and rate heterogeneity in the EQ-5D-5L valuation. Health Qual Life Outcomes. 2024 Jul 13;22(1):55. doi: 10.1186/s12955-024-02271-w. PubMed PMID: 39003479; PubMed Central PMCID: PMC11555889.
4. van Til JA, Pearce A, Ozdemir S, Hollin IL, Peay HL, Wu AW, Ostermann J, Deal K, **Craig BM**. Role Preferences in Medical Decision Making: Relevance and Implications for Health Preference Research. Patient. 2024 Jan;17(1):3-12. doi: 10.1007/s40271-023-00649-4. Epub 2023 Oct 24. PubMed PMID: 37874464; PubMed Central PMCID: PMC10769916.
5. Jumamyradov M, **Craig BM**, Rivero-Arias O, Jakubczyk M. Child health valuation protocol for a discrete choice experiment comparing paired comparison and kaizen tasks and estimating US EQ-5D-Y-3L values on an experience scale. BMJ Open. 2023 Oct 24;13(10):e077256. doi: 10.1136/bmjopen-2023-077256. PubMed PMID: 37879694; PubMed Central PMCID: PMC10603523.
6. Karim S, **Craig BM**, Tejada RA, Augustovski F. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values. Health Qual Life Outcomes. 2023 Jan 2;21(1):1. doi: 10.1186/s12955-022-02079-6. PMID: 36593473; PMCID: PMC9808950.
7. Karim S, **Craig BM**, Vass C, Groothuis-Oudshoorn CGM. Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review. Pharmacoeconomics. 2022 Dec;40(12):1173-1191. doi: 10.1007/s40273-022-01169-4. Epub 2022 Sep 6. PMID: 36066794; PMCID: PMC9676947.

18. Poteet S, **Craig BM.** The Value Employees Place on Health Insurance Plans: A Discrete-Choice Experiment. Appl Health Econ Health Policy. 2019 Dec;17(6):817-825. doi: 10.1007/s40258-019-00507-1 PMID: 31423545
19. Hartman JD, **Craig BM**. Does Device or Connection Type Affect Health Preferences in Online Surveys? Patient. 2019 Dec;12(6):639-650. doi: 10.1007/s40271-019-00380-z. PMID: 31364022
20. Norman R, **Craig BM,** Hansen P, Jonker MF, Rose J, Street DJ, Mulhern B. Issues in the Design of Discrete Choice Experiments. Patient. 2019 Jun;12(3):281-285. doi: 10.1007/s40271-018-0346-0. PMID: 30446958
21. **Craig BM**, Rand K, Bailey H, Stalmeier PFM. Quality-Adjusted Life-Years without Constant Proportionality. Value Health. 2018 Sep;21(9):1124-1131. doi: 10.1016/j.jval.2018.02.004. Epub 2018 Mar 27. PMID: 30224118
22. Hartman JD, **Craig BM**. Examining the Association Between Maternal Smoking During Pregnancy and Child Behavior Problems Using Quality-Adjusted Life Years. Matern Child Health J. 2018 Dec;22(12):1780-1788. doi: 10.1007/s10995-018-2577-z. PMID: 29995297
23. Ramos-Goñi JM, **Craig BM**, Oppe M, Ramallo-Fariña Y, Pinto-Prades JL, Luo N, Rivero-Arias O. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. Value Health. 2018 May;21(5):596-604. doi: 10.1016/j.jval.2017.10.023. Epub 2017 Dec 2. PMID: 29753358
24. **Craig BM**, Rand K. Choice Defines QALYs: A US Valuation of the EQ-5D-5L. Med Care. 2018 Jun;56(6):529-536. doi: 10.1097/MLR.0000000000000912. PMID: 29668646
25. Jakubczyk M, **Craig BM**, Barra M, Groothuis-Oudshoorn CGM, Hartman JD, Huynh E, Ramos-Goñi JM, Stolk EA, Rand K. Choice Defines Value: A Predictive Modeling C0.7 (h)1h E, Ramos

54. Tarn DM, Young HN, **Craig BM**. Development of the patient approach and views toward healthcare

18. **Craig BM**, Busschbach JJV, Salomon J. Ordinal valuation of health states: a seven country study. Proceedings of the 23rd Scientific Plenary Meeting of the EuroQol Group, 415-435, August 2006.

Other Research and Creative Works

1. **Craig BM**, Gonzálugusrks

Scientific Abstracts/Podium Presentations/Poster Presentations

1. **Craig BM**, Peasgood T, Pham M, Rencz F, A Direct Comparisons of the Measurement and Conceptual Properties of the EQ-5D-5L and PROMIS®-16 in a US General Population Sample, v1.8 (d)-M( )Tj/TT1 1 Tf-0.001 T

17. Craig BM, Rand K. Choice Defines QALYs: A US Valuation of the EQ-5D-5L. International Society for Pharmacoeconomics and Outcomes Research, 23rd Annual Meeting, Baltimore, Maryland, USA, May 2018.
18. Poteet S, **Craig BM**, US EQ-5D-5L Values by Self-reported Health. [poster]. EuroQol Group. 3rd EuroQol Academy Meeting. Budapest, Hungary. March 2018.
19. **Craig BM**. Lexicographic preferences in lifespan: an inconvenient truth. International Academy of Health Preference Research. 7th Meeting. Glasgow, UK. November 2017.
20. Poteet S, **Craig BM,** Brown D. Lexicographic Preferences in U.S. Health Insurance Marketplace: the case of single employees. International Academy of Health Preference Research. 7th Meeting. Glasgow, UK. November 2017.
21. Hartman J, **Craig BM**. Learning Curves and Sequence Effects. International Academy of Health Preference Research. 7th Meeting. Glasgow, UK. November 2017.
22. **Craig BM**, Rand-Hendriksen K. US Valuation of the EQ-5D-

38. **Craig BM**, Mitchell SA. Examining the Value of Menopausal Symptom Relief among US Women, International Academy of Health Preference Research. 2nd Meeting. Brisbane, Queensland, Australia. September 29, 2015.
39. Santos M, Monteiro AL, **Craig BM**. Further evidence on EQ-5D-5L preference inversion: A Brazil/US Collaboration, EuroQol Group. 32st Plenary Meeting. Krakow, Poland. September 2015.
40. **Craig BM**. Does changing the order of the EQ-5D questions change their responses? [poster], EuroQol Group. 32st Plenary Meeting. Krakow, Poland. September 2015.
41. Hartman J, **Craig BM**. Comparison of PROMIS and EQ-5D Quality-adjusted Life Years [poster], EuroQol Group. 32st Plenary Meeting. Krakow, Poland. September 2015.
42. **Craig BM**, Brown DS, Reeve BB. The Value Adults Place on Child Health and Functional Status [poster], International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
43. **Craig BM**, Greiner W, Brown DS, Reeve BB. Valuation of Child Health-related Quality of Life in the United States [poster], International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
44. **Craig BM**, Mitchell SA. The Value Women Place on Menopausal Symptoms [poster], , International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
45. Hartman J, **Craig BM**. Owens MA, Brown DS. Prevalence and Losses in Quality-Adjusted Life Years of Child Health Conditions: a Burden of Disease Analysis [poster], International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
46. Runge SK, **Craig BM**, Reeve BB. Choosing between the PROMIS Global And EQ-5D for Comparative Effectiveness Research: Are They Really Different?, 20th Annual Meeting, Phila3.7 (st)-1.7 (ed)-3.8 (L)-c 0

57. Ratcliffe J, Chen G, **Craig BM**, Stevens K, Brazier J, Huynh E, Sawyer M, Roberts R, Flynn TN. Assessing the health related quality of life of Australian adolescents: findings from application of the EQ-5D-Y in a community based on-line survey [poster], EuroQol Group. 30th Plenary Meeting. Montreal, Canada. September 2013.
58. **Craig BM,** Brown DS, Cunningham C, Greiner W, Reeve BB. United States Valuation of Child Health Outcomes [poster], International Society for Pharmacoeconomics and Outcomes Research, 15th Annual European Congress, Berlin, Germany, November 2012.
59. **Craig BM**, Watson V, Busschbach JJV. Choice-based valuation of the SF-12v1[poster], International Society for Pharmacoeconomics and Outcomes Research, 15th Annual European Congress, Berlin, Germany, November 2012.
60. **Craig BM**, Watson V. Choice-based Valuation of the SF-12. The 4th Conjoint Analysis in Health Conference. Orlando, Florida, USA. March 2012.
61. Lengacher CA, Jim H, Reich R, Pracht E, **Craig BM**, Ramesar R, Carranza I, Paterson C, Budhrani P, Millette L, Hogue DL, Wooten K, Mogos M, Johnson Mallard V, Santiago S, Miglore M, Dameron M, Kip KE. Improving Quality of Life in Breast Cancer Survivors: The Cost-Effectiveness of Mindfulness Based Stress Reduction [poster]. 9th Annual Conference of the American Psychosocial Oncology Society. Miami, Florida, USA. February 2012.

75. Abimbola T, **Craig BM**, Rollison DE, Kumar A, Giuliano A. Evidence synthesis for modeling the natural history of anal penile and oropharyngeal cancers [poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 16th Annual Conference. Orlando, Florida, USA. May 18, 2009.
76. **Craig BM**, Abimbola T, Rollison DE, Kumar A, Giuliano A. Modeling Anal/Penile Cancer in HVP Vaccination [poster]. International Papillomavirus Society (IPVS). 25th Annual Conference. Malmö, Sweden. May 12, 2009.
77. **Craig BM**, Busschbach JJV, Oppe M. Revisiting the estimation of QALYs [workshop]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 14th Annual Conference. Orlando, Florida, USA. May 18, 2009.
78. **Craig BM**, Oppe M. From a different angle: A novel approach to health valuation. Second Conjoint Analysis in Health Conference. Delray Beach, Florida, USA. March 26, 2009.
79. **Craig BM**, Renewing the War on Cancer [Plenary]. Association of Cancer Executives. 15th Annual Meeting. Sarasota, Florida, USA. February 16, 2009.
80. Gu NY**, Craig BM**, Doctor J. Diagnosing the EQ-5D items using the Rasch Models in a US Representative Sample. EuroQol Group. 25th Plenary Meeting. Lake Maggiore, Italy. September 2008.
81. Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, **Craig BM**. Argentine Valuation of the EQ-5D Health States. EuroQol Group. 25th Plenary Meeting. Lake Maggiore, Italy. September 2008.
82. **Craig BM**, Busschbach JJV. Sample Size and State Selection Considerations in EQ-5D Valuation Studies. EuroQol Group. 25th Plenary Meeting. Lake Maggiore, Italy. September 2008.
83. **Craig BM**, Busschbach JJV, Salomon J. International Valuation Set for EQ-5D Health States [poster]. American Society of Health Economists (ASHE), Equity and Efficiency in Health and Healthcare. 2nd Biennial Conference. Durham, North Carolina, USA. June 2008.
84. **Craig BM**, Busschbach JJV, Salomon J. International Valuation Set for EQ-5D Health States [poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 13th Annual Conference. Toronto, Ontario, Canada, May 2008.
85. **Craig BM**, Busschbach JJV, Salomon J. International Valuation Set for EQ-5D Health States. EuroQol Group. 24th Plenary Meeting. Der Haag, the Netherlands. September 2007.
86. **Craig BM**, Busschbach JJV, Salomon J. Ordinal valuation of health states: an eight country study [poster]. International Health Economics Association. (iHEA) 6th World Congress. Copenhagen, Denmark. July 2007.
87. **Craig BM**, Strassels S. Out-Of-Pocket Prices of Opioid Analgesics in the United States [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 12thAnnual Conference. Washington, District of Columbia, USA. May 2007.
88. **Craig BM**, Busschbach JJV, Salomon J. Ordinal valuation of health states: a seven country study. EuroQol Group. 23rd Annual Conference. Barcelona, Spain. September 2006.
89. **Craig BM**, Deb P. A multimodal model of health care prices American Society of Health

95. Ramachandran S, **Craig BM**, Coons SJ. Equivalence of Paper and Touch Screen Versions of the EQ-5D Visual Analog Scale (EQ-VAS) [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 10th Annual Conference. Washington, District of Columbia, USA. May 2005.
96. Lundy JJ, **Craig BM**. The Impact of Medicare Part D on Economic Barriers to Prescription Medications among Beneficiaries with Multiple Sclerosis [poster]. International Society of Pharmacoeconomics and Outcomes Research (Lhan[oPd

1. Eliciting health preferences in small and heterogeneous groups: an introduction to preference paths and their kaizen tasks with three examples, Evidera, London, UK. February 2022.
2. Role Preferences in Medical Decision Making [Moderator], Health Preference Research Special Interest Group, International Health Economics Association, South Africa. January 2022.
3. A Guide to Observable Differences in Stated Preference Evidence, International Academy of Health Preference Research, Tampa, Florida, USA. December 2021.
4. Kaizen tasks in health preference research, Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, England, UK. November 2021.
5. Health Preference Research, Health Technology & Services Research, University of Twente, Enschede, The Netherland, August 2021.
6. Preference paths & their kaizen tasks for health valuation, EuroQol Webinar Series, online, July 2021.
7. Extending choice analysis beyond logits, Seminar, Department of Economics, Curtin University, Perth, Western Asitr,naPer,na8 (ch)Tw 0.754,]TJ0 Tc d0.00este-3.7 (.397 (c))2.4 (u)-1.7, Se(es2c),21.

w 1.7 (e-3.c)-5.1 ((P)-2.4 s(er)-1.4 (en)-3.8 aer)-1.4 chn1.7 (a(er)-1.3 (u)-3.7 ((T)-2 (k)-3.8 ((al)-1.7(en)-3.8u f)-1.3 (o)-3.7(ed)-3.8 (e,)-24

23. Choice Defines Value: Turning preferences of multiple stakeholders into evidence for health care decision making, International Society for Pharmacoeconomics and Outcomes Research, 21st Annual Meeting, Palais des Congrès de Montréal, Montreal, Quebec, Canada, June 2014 (workshop).
24. Choice Defines Value: New Approaches to evaluating multiple treatment attributes and health outcomes, International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, New Orleans, Louisiana, USA, May 2013 (workshop).
25. Discrete Choice and Health Valuation, Bundesverband Managed Care e.V., Berlin, Germany, November 2012.
26. Choice Defines Value: New Approaches to estimating QALYs, HYEs, and efficiency frontiers, International Society for Pharmacoeconomics and Outcomes Research, 15th Annual European Congress, Berlin, Germany, November 6, 2012 (workshop).
27. US valuation of child health outcomes, Youth Taskforce, EuroQol Group, Amsterdam, the Netherlands, May 2012.
28. How to translate PROs into Irish QALYs using the internet, Irish National Centre for Pharmacoeconomics, Trinity College Dublin, Dublin, Ireland. July 2011.
29. Incorporating Patient Reported Outcome Measures into US Comparative Effectiveness Research, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, UK, June 2011
30. How to translate PRO into QALYs using the internet, Centre for Health Economics, University of York, York, England, UK. June 2009.
31. Online Technological Constraints in Experimental Health Economics, Health Economics Research Unit, University of Aberdeen, Aberdeen, Scotland, UK, June 2011.
32. The Emperor's New Clothes: revisiting QALY estimation, Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, England, UK. July 2009.
33. Towards a more universal approach in health valuation, Centre for Health Economch,o2.3 (y of)2.6 (.3 (ofk of)2.7 (e)

31.

2. The Future of Health Preferences in Regulatory and Clinical Decisions, Center for Devices and Radiological Health, U.S. Food and Drug Administration. September 2017
3. The Future of Health Preferences in Regulatory and Clinical Decisions, Arkansas Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, Arkansas, May 5, 2017
4. The Future of Health Preferences in Regulatory and Clinical Decisions, Patient Voice Seminar, Duke University,

24.

July 2005